Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Active surveillance of early prostate cancer: rationale, initial results and future developments

Prostate Cancer and Prostatic Diseases volume 7, pages 184–187 (2004)Cite this article

Abstract

Active surveillance is a new strategy that aims to individualise therapy by selecting only those men with significant cancers for curative therapy based on early evidence of disease progression. Active surveillance must be distinguished from watchful waiting, which for decades has described a policy of observation with the use of palliative treatment for symptomatic progression. The rationale for active surveillance is discussed, based on our knowledge of the natural history of PSA-detected early prostate cancer. The initial results of active surveillance have demonstrated its feasibility. Ongoing studies seek to optimise the active surveillance protocol, and to determine the long-term outcomes. Looking ahead, dietary intervention in men on active surveillance could become an important new paradigm for prostate cancer management.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Albertsen PC, Hanley JA, Gleason DF, Barry MJ . Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–980.

    Article  CAS  Google Scholar 

  2. Chodak GW et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–248.

    Article  CAS  Google Scholar 

  3. Johansson JE et al. Fifteen-Year survival in prostate cancer. A prospective, population- based study in Sweden. JAMA 1997; 277: 467–471.

    Article  CAS  Google Scholar 

  4. Draisma G et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–878.

    Article  Google Scholar 

  5. Etzioni R et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981–990.

    Article  Google Scholar 

  6. McGregor M, Hanley JA, Boivin JF, McLean RG . Screening for prostate cancer: estimating the magnitude of overdetection. Can Med Assoc J 1998; 159: 1368–1372.

    CAS  Google Scholar 

  7. Nicholson PW, Harland SJ . Survival prospects after screen-detection of prostate cancer. BJU Int 2002; 90: 686–693.

    Article  CAS  Google Scholar 

  8. Steineck G et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–796.

    Article  Google Scholar 

  9. Stamey TA et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076–1083.

    Article  CAS  Google Scholar 

  10. Schmid HP, McNeal JE, Stamey TA . Clinical observations on the doubling time of prostate cancer. Eur Urol 1993; 23 (Suppl 2): 60–63.

    Article  Google Scholar 

  11. Parker CC, Dearnaley DP . The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998; 49: 103–110.

    Article  CAS  Google Scholar 

  12. Sandier HM et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radial Oncol Biol Phys 2000; 48: 629–633.

    Article  Google Scholar 

  13. McLaren DB, McKenzie M, Duncan G, Pickles T . Watchful waiting or watchful progression?: prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 342–348.

    Article  CAS  Google Scholar 

  14. Choo R et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615–620.

    Article  CAS  Google Scholar 

  15. Choo R et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664–1669.

    Article  Google Scholar 

  16. Carter HB, Walsh PC, Landis P et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231–1234.

    Article  Google Scholar 

  17. Epstein JI, Walsh PC, Carter HB . Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166: 1688–1691.

    Article  CAS  Google Scholar 

  18. Choo R, Do V, Sugar L et al. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol 2004; 11: 2118–2222.

    CAS  PubMed  Google Scholar 

  19. Donovan et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1–88.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK

    C Parker

Authors
  1. C Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Parker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, C. Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis 7, 184–187 (2004). https://doi.org/10.1038/sj.pcan.4500720

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500720

Keywords

This article is cited by

Search

Advanced search

Quick links